Life Biosciences' OSK gene cocktail ER-100 passed 56 days in three glaucoma patients with no serious safety issues and visual field gains in two of them; this independently unverified early signal led to a tripled dose.

Rewinding the internal clock of an aging cell spent a decade as a mouse experiment. ER-100, an experimental gene therapy from Boston-based Life Biosciences, has now carried that idea into the first human eye, and the Phase 1 study has released its earliest data. According to the announcement carried on lifebiosciences.com, three participants with open-angle glaucoma completed 56 days of follow-up with no serious safety flags, while visual field testing recorded striking gains in two of them. The result marks the first milestone in moving partial epigenetic rejuvenation from the laboratory into the clinic.

How the three-gene cocktail works

The method traces back to the four Yamanaka factors that can turn mature cells into stem cells. Because the c-MYC member of the original quartet is linked to tumor formation, it was removed from the formula, leaving the three-gene OSK cocktail of OCT4, SOX2 and KLF4. The goal is not to reset the cell all the way back but to nudge its gene-expression pattern toward a youthful state while preserving its identity. Delivery uses a modified adeno-associated virus (AAV2) given once into the eye. After the vector settles in, participants take a daily doxycycline pill for eight weeks, which acts as a switch deciding when the genes turn on. A tapering course of corticosteroid accompanies the treatment to calm any immune reaction against the carrier.

Day-56 readout: safety bar cleared, vision signal noted

At the starting dose of 2x10 to the 11 vector genomes per eye, none of the three participants reported a dose-limiting toxicity, an event needing special monitoring, or a serious adverse event. The mild complaints observed were attributed not to the molecule itself but to the injection procedure, the steroid course, or the patients' underlying conditions. On standard Humphrey visual field testing, two of the three showed sensitivity gains above 4 decibels across at least 28 percent of tested points. That vision readout rests solely on a company announcement and remains an independently unverified early signal; Phase 1 studies are designed around safety, and no efficacy conclusion can be drawn from a three-person open-label group.

With a positive opinion from the safety board (DSMB), the glaucoma arm escalated to triple the dose, 6x10 to the 11 vector genomes, and the study continues. The registered protocol NCT07290244 targets 18 participants in total: 12 with open-angle glaucoma and 6 with NAION. Per the schedule compiled by hormonesynergy.com, the glaucoma arm advances stepwise with sentinel participants; the NAION arm opens once a dose is selected through this gradual dose climb . Primary completion is listed as May 2027, with participants followed under an extended multi-year observation plan.

A decade-long ladder from mice to monkeys

The scientific footing for the human trial is a mouse study published in Nature in 2020 and indexed by NIH records. Lu and colleagues switched on OSK genes in the retinal ganglion cells of aged mice and found DNA methylation patterns growing youthful again, injured nerve fibers regrowing, and vision returning in both a glaucoma model and old animals. The same work showed the effect depends on the DNA repair enzymes TET1 and TET2. In more recent mouse experiments from the David Sinclair group, animals with pressure-induced glaucoma-like damage were split into four arms; in the arm with continuous gene activity, vision returned to healthy levels within two months and held for nearly 11 months. Lifespan, the research news outlet, covered those animal results in depth. On the clinical side, theophthalmologist.com reported the first patient dosing in July 2026, while a bulletin distributed via GlobeNewswire on October 1 announced interim data would be presented on October 8 at the Eyecelerator meeting in New Orleans.

Why the eye goes first

The retinal signaling cells damaged in glaucoma and NAION cannot regenerate; once such a cell dies, the vision loss is permanent. Today's glaucoma drugs and surgeries only lower intraocular pressure and slow the process without bringing dead cells back, and NAION has no approved therapy at all. Figures quoted by glaucoma.org put the global glaucoma population near 80 million, projected to pass 111 million toward 2040, while work cited by the BrightFocus foundation notes there is still not a single approved drug that protects the retina. The eye being an enclosed, easily monitored organ also makes it a sensible starting point for such first-in-human attempts.

In short, ER-100 is the first clinical test of the theory that aging is largely the erasure of epigenetic information rather than accumulated damage. Clearing the safety bar in the first three-person step and moving to a higher dose is encouraging for the field, yet the vision signal remains a small, uncontrolled, company-sourced observation. The next two years, with dose steps and the NAION arm delivering data, will put that early hope to the test.